Current Challenges and New Opportunities of Hybrid Nanoparticles for Diagnosis and Treatment of Cancer

Ali  Tarighatnia; Golshan  Mahmoudi; Mahnaz  Kiani; Nader D.  Nader

doi:10.18502/fbt.v11i1.14503

Ali Tarighatnia Department of Medical Physics, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Golshan Mahmoudi Medical Imaging Technology Department, School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran
Mahnaz Kiani Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran
Nader D. Nader Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA

DOI: https://doi.org/10.18502/fbt.v11i1.14503

Keywords: Hybrid Nanoparticles; Contrast Agents; Cancer Diagnosis; Cancer Treatment.

Abstract

Hybrid Nanoparticles (NPs) have emerged as promising tools in cancer diagnosis and treatment, offering the potential for early detection and precise eradication of malignant cells by integrating diverse materials. However, navigating this domain's intricacies, limitations, and hurdles underscores the importance of thoughtful decision-making. This editorial provides a comprehensive exploration of the merits and challenges of nanotechnology in the context of cancer diagnosis, therapy, and theranostics. It sheds light on the current applications and delves into the promising prospects in this field. This editorial aims to foster a deeper understanding of the intricacies of designing efficient protocols for hybrid NP production, contributing to advancing cancer management strategies.